Roche: FDA grants immunotherapy Tecentriq priority review
(CercleFinance.com) - The U.
S. Food and Drug Administration has granted priority review for Roche's immunotherapy Tecentriq in combination with chemotherapy or other chemotherapies to treat patients with a specific type of metastatic lung cancer.
A priority review designation is granted to drugs that the FDA has determined to have the potential to provide significant improvements in the treatment of a disease, the Swiss drugmaker said.
It deals here with the first-line treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
The FDA is expected to make a decision by September 2018, Roche added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
S. Food and Drug Administration has granted priority review for Roche's immunotherapy Tecentriq in combination with chemotherapy or other chemotherapies to treat patients with a specific type of metastatic lung cancer.
A priority review designation is granted to drugs that the FDA has determined to have the potential to provide significant improvements in the treatment of a disease, the Swiss drugmaker said.
It deals here with the first-line treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
The FDA is expected to make a decision by September 2018, Roche added.
Copyright (c) 2018 CercleFinance.com. All rights reserved.